×
Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Europe Gastrointestinal Drugs Market

ID: MRFR/Pharma/0165-HCR
85 Pages
Kinjoll Dey
October 2025

Europe, Middle East and Africa Gastrointestinal Drugs Market Research Report, by Drug Category (Acid Neutralizers, Laxatives and Antidiarrheal, Anti-inflammatory drugs), By Route of Administration (Oral, Parenteral, Rectal), By Disease Type (Gastroesophageal Reflux Disease, Inflammatory Bowel Disease), by end user (Hospital Pharmacies, Retail Pharmacies) - Forecast till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Europe Gastrointestinal Drugs Market Infographic
Purchase Options

Europe Gastrointestinal Drugs Market Summary

The Europe, Middle East and Africa Gastrointestinal Drugs market is projected to grow significantly over the next decade.

Key Market Trends & Highlights

Europe, Middle East and Africa Gastrointestinal Drugs Key Trends and Highlights

  • The market valuation is expected to increase from 11.8 USD Billion in 2024 to 23.8 USD Billion by 2035.
  • A compound annual growth rate (CAGR) of 6.58 percent is anticipated from 2025 to 2035.
  • The growth trajectory suggests a robust demand for gastrointestinal drugs across the region.
  • Growing adoption of advanced therapeutic options due to increasing prevalence of gastrointestinal disorders is a major market driver.

Market Size & Forecast

2024 Market Size 11.8 (USD Billion)
2035 Market Size 23.8 (USD Billion)
CAGR (2025-2035) 6.58%

Major Players

AstraZeneca Plc., Johnson & Johnson, Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Valeant Pharmaceuticals Inc., Sanofi Ltd., Abbott Laboratories, Allergan Plc, Bayer AG, Janssen Biotech Inc., AbbVie Inc., GlaxoSmithKline Plc., Boehringer Ingelheim GmbH

Key Companies in the Europe Gastrointestinal Drugs Market market include

Report Scope

Attribute/Metric Details
  Market Size 2032  USD 20.01 Billion
  CAGR   6.0% (2024-2032)
  Base Year   2023
  Forecast Period   2024-2032
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered Drug Category, Route of Administration, Disease Type  and End-user
  Geographies Covered North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors AstraZeneca Plc.(UK), Johnson & Johnson (US), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Valeant Pharmaceuticals Inc. (US), Sanofi Ltd. (France), Valeant (US), Abbott Laboratories(US), Allergan Plc (US), Bayer AG (Germany), Janssen Biotech Inc. (US), AbbVie Inc. (US), Janssen Biotech (US), GlaxoSmithKline Plc. (UK), Boehringer Ingelheim GmbH (Germany)
  Key Market Opportunities Increasing awareness about the availability of treatment
  Key Market Drivers Increasing prevalence of many gastrointestinal disease

Market Highlights

Author
Kinjoll Dey
Research Analyst Level I

He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

Leave a Comment

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions